Matching slides 303,780
Current window 203,791-203,820
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

203,791-203,820 of 303,780

filter-aware
06
The slide uses a 2x2 grid layout to organize the portfolio by therapeutic area.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
07
The slide uses a numbered list to outline the investment thesis and a callout box for specific 2022 milestones.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
08
The slide uses a horizontal bar chart format to represent clinical trial stages for various assets.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
09
Includes regulatory status and financial terms of the licensing deal.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
10
Slide highlights clinical development status and key value propositions for two lead assets.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
11
The slide uses a structured grid layout to present seven distinct product development programs.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
12
The slide uses a flow-like diagram to connect internal strengths to external market trends, supported by a list of recent industry transactions.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
14
Dare Bioscience | Investor Presentation Deck | 50 slidesDare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations Beat · Financials1 hit
15
The slide uses a callout box to summarize the upcoming milestones for the company's pipeline.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
16
Includes regulatory status and commercial partnership details.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations Beat · Product1 hit
17
The slide uses a three-row layout to contrast the problem, current limitations, and the proposed solution.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
18
Slide 18 of the deck.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
19
The slide highlights a key business development milestone involving a $10M upfront payment and potential $182.5M in milestones.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
20
Standard pharmaceutical ISI (Important Safety Information) slide.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
21
This slide provides regulatory/clinical disclosure information regarding special populations.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
23
The slide uses a combination of a demographic projection chart and a hub-and-spoke diagram of successful products to establish market scale.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
24
Uses a tree-like decomposition to show the total addressable market and its sub-segments.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
25
The slide uses a vertical effectiveness scale to position existing methods and highlight the 'missing' product category.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
26
The slide uses a comparison framework to map user needs to product capabilities.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution1 hit
27
Highlights the validation of the product by a major industry player (Bayer) and the financial terms of the deal.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
28
Includes a testimonial/quote from a partner at the bottom.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
29
Includes specific clinical data points from a Postcoital Test (PCT) study.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
30
The slide highlights the lack of existing FDA-approved therapies for FSAD.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
31
Uses a visual inequality symbol to emphasize the distinction between FSAD and HSDD.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
32
The slide uses a two-part structure: global meta-analysis data followed by US-specific market sizing.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
33
The slide uses a bulleted list to define the product profile and concludes with a strong market gap statement regarding FSAD.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
34
The slide outlines the methodology and status of a clinical trial.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
35
The slide uses clinical trial data to justify the pivot to a topical delivery mechanism.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
36
Includes both tabular pharmacokinetic data and a line chart showing plasma concentration over time.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit
37
Study design is a small N=6 crossover trial.Dare Bioscience | Investor Presentation Deck | 50 slides · Daré Bioscience
Pitch deck Investor relations 1 hit